Leukemia represents a genetically heterogeneous group of hematologic malignancies. While most genomic studies have historically centered on somatic nuclear mutations, a growing body of evidence underscores the critical contribution of mitochondrial DNA (mtDNA) alterations to leukemogenesis. In a recent review published in Blood Science, researchers examine the landscape of mtDNA mutations, copy number variations, and sequencing technologies, illuminating their mechanistic roles in disease pathogenesis, prognostication, and clonal evolution.Mitochondrial Genetics: A Distinct Layer of Complexity
Mitochondria, as essential energy-generating organelles, possess a compact 16.5 kb circular genome encoding 37 genes critical for oxidative phosphorylation. Unlike nuclear DNA, mtDNA lacks introns and is more vulnerable to damage due to minimal histone protection and limited repair capacity. These features contribute to a ten-fold higher mutation rate compared to nuclear DNA. Additionally, mtDNA exists in hundreds to thousands of copies per cell, enabling robust detection of genetic alterations and facilitating single-cell resolution studies of clonal dynamics.
Study Framework and Methodological Approaches
This review synthesized findings from a wide array of studies analyzing mitochondrial genomic abnormalities in leukemia. High-throughput sequencing platforms—including whole-genome sequencing, digital PCR, and single-cell transcriptomics—were utilized to assess mutation burden and mtDNA copy number alterations. The review also highlights innovative methodologies for integrating mitochondrial data with nuclear profiles, particularly in longitudinal clonal tracing studies.
Results: Mutation Landscape and Copy Number Alterations
Widespread somatic mtDNA mutations have been identified in leukemia. In chronic lymphocytic leukemia (CLL), over half of the analyzed cells harbored at least one mtDNA mutation. Pediatric acute myeloid leukemia (AML) samples revealed hotspot mutations in the noncoding D-loop region—such as T489C—associated with disease relapse. ND6, a protein-coding mitochondrial gene, showed a mutation frequency of 32.65% in patients, underscoring the functional relevance of mtDNA alterations in leukemic pathogenesis.
Altered mtDNA copy number represents another key feature of mitochondrial dysfunction. AML patients demonstrated a 9-fold increase in mtDNA content compared to healthy individuals (P < .0001). Upregulation of mitochondrial transcription factors such as TFAM and POLRMT correlated with reduced overall survival. Conversely, in acute promyelocytic leukemia (APL), elevated mtDNA content was associated with lower relapse rates post-chemotherapy, highlighting context-dependent implications of mitochondrial biogenesis.
Pathophysiological Significance and Clonal Tracking Potential
The biological consequences of mitochondrial genomic abnormalities extend beyond metabolic reprogramming. Mutations in genes encoding electron transport chain (ETC) components perturb redox balance and chromatin structure, contributing to leukemic transformation. A unique advantage of mtDNA mutations lies in their stability and abundance, which allows them to function as endogenous genetic barcodes for lineage tracing. Single-cell multi-omic technologies such as mtscATAC-seq enable the simultaneous capture of chromatin states and mitochondrial genotypes, providing high-resolution insight into subclonal architecture and disease evolution.
Clinical Implications and Prognostic Associations
Mounting evidence suggests that mtDNA alterations may serve as clinically relevant biomarkers. In AML, somatic ND4 mutations have been associated with significantly improved relapse-free and overall survival (P = .017 and P = .021, respectively). In contrast, mutations affecting ETC complexes I through IV are linked to poor outcomes, underscoring their functional impact on mitochondrial metabolism. Additionally, variants in the hypervariable regions of the D-loop—such as 16311T→C—have been correlated with unfavorable prognosis in pediatric AML. However, findings regarding mtDNA copy number as a prognostic biomarker in adult AML remain inconsistent, warranting further investigation.
Conclusion
Mitochondrial genomic instability, encompassing somatic mutations and copy number changes, contributes substantively to leukemogenesis and disease progression. These alterations offer unique advantages as high-resolution clonal markers and potential prognostic indicators. As multi-omic approaches continue to evolve, integrating mitochondrial genomics with nuclear data will enhance the precision of leukemia classification, risk stratification, and therapeutic monitoring.
Click the link to view the original article：
